Study Backs Decision to Move Forward With Pfizer Vaccine Candidate
Study results from a phase 1 trial looking at 2 RNA-based severe acute respiratory syndrome coronavirus 2 vaccine candidates give further insight into the candidates’ safety profiles.
Results of a phase 1 study of healthy adults receiving either of Pfizer and BioNTech’s 2 RNA-based vaccine candidates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) supported the decision about which one to advance to later trials, researchers wrote Wednesday.
Writing in
The study is part of Pfizer and BioNTech’s larger trial to find a vaccine to prevent SARS-CoV-2 from causing coronavirus disease 2019 (COVID-19). Previous studies conducted in Germany and the United States narrowed down the companies’ investigation to these 2 candidates.
Researchers have begun trial enrollment for a phase 2/3 international trial that will assess the safety and efficacy profile of BNT162b2 at the 30-μg dose level in up to 44,000 participants aged 18 to 85 years.
In the phase 1 study to evaluate safety and immunogenicity, a total of 195 healthy participants underwent a 4:1 randomization in 13 groups to either receive a placebo or vaccine candidate. Each group had 15 participants, where 12 would receive a vaccine candidate and 3 would receive a placebo.
Participants were aged 18 to 55 years and 65 to 85 years.
The ongoing, placebo-controlled, observer-blinded, dose-escalated phase 1 trial tested dosages of 10 μg, 20 μg, 30 μg, and 100 μg.
All of the groups received 2 doses administered 21 days apart, except for the group receiving 100 μg of BNT162b1, who only received 1 dose because patients who received the active vaccine experienced reactogenicity.
Severe systemic reactions, including fatigue, headache, chills, muscle pain, and joint pain, were reported in a small number of younger patients who received BNT162b2. However, none of the older recipients of BNT162b2 reported severe reactions.
The study’s results come days after pauses were announced for Johnson & Johnson’s and Eli Lilly’s vaccine trials. AztraZeneca’s vaccine trial was also temporarily halted in late September.
Amid the vaccine race, in response to being mentioned by the president during the first presidential debate, Pfizer’s CEO Albert Bourla
In September,
Reference
Walsh, EE, French RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. Published October 14 2020. doi:10.1056/NEJMoa2027906
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025